2026-04-29T08:58:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/151952024-09-27T08:47:59Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Díez-Díez, Miriam author Amorós-Pérez, Marta author de la Barrera, Jorge author Vázquez, Enrique author Quintas, Ana author Pascual-Figal, Domingo A author Dopazo, Ana author Sanchez-Cabo, Fatima author Kleinman, Monica E author Gordon, Leslie B author Fuster, Valentin author Andres, Vicente author Fuster, Jose J. author Pascual-Figal, Domingo A. author Kleinman, Monica E. author Gordon, Leslie B. author Fuster, José J. author 2022-06-25 Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the accumulation of a truncated form of the lamin A protein called progerin. HGPS patients exhibit several features of accelerated aging and typically die from cardiovascular complications in their early teens. Previous studies have shown normal hematological parameters in HGPS patients, except for elevated platelets, and low levels of lamin A expression in hematopoietic cells relative to other cell types in solid tissues, but the prevalence of CHIP in HGPS remains unexplored. To investigate the potential role of CHIP in HGPS, we performed high-sensitivity targeted sequencing of CHIP-related genes in blood DNA samples from a cohort of 47 HGPS patients. As a control, the same sequencing strategy was applied to blood DNA samples from middle-aged and elderly individuals, expected to exhibit a biological age and cardiovascular risk profile similar to HGPS patients. We found that CHIP is not prevalent in HGPS patients, in marked contrast to our observations in individuals who age normally. Thus, our study unveils a major difference between HGPS and normal aging and provides conclusive evidence that CHIP is not frequent in HGPS and, therefore, is unlikely to contribute to the pathophysiology of this accelerated aging syndrome. Geroscience . 2022 Jun 25. 2509-2715 http://hdl.handle.net/20.500.12105/15195 35752705 10.1007/s11357-022-00607-2 2509-2723 GeroScience Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome.